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 Purpose 
 In this chapter we will provide a brief primer on 
urologic care with a focus on the particular needs 
of LGBT persons. It is our hope that this manu-
script will be of use to primary care physicians 
who will see LGBT persons with urologic issues 
and to urologists who may not be familiar with 
issues germane to the LGBT community. We will 
address general urologic issues but will focus on 
urologic issues for which there is evidence of 
signifi cant differences between LGBT and non- 
LGBT patients. 
 Learning Objectives 
•  Identify at least three ways in which urologic 
healthcare is sensitive for LGBT patients 
 (PC2, PBLI1, PBLI1, ICS2) 
•  Describe lower urinary tract symptoms and how 
they may manifest in LGBT patients  (PC5) 
•  Describe sexual function and dysfunction in 
LGBT patients  (PC5) 
•  Discuss opportunities for screening for uro-
logic malignancy in LGBT patients  (PC3, 
PC4) 
 Urologic  Healthcare for the LGBT 
Patient 
 A safe and welcoming environment is the foun-
dation of productive encounters between health 
care providers and patients. In Western societies, 
heterosexuality and gender identity concordant 
with genital sex is the presumed norm. Individuals 
who are sexually attracted to members of the 
same sex (e.g. lesbian, gay, bisexual) and persons 
whose biological sex differs from their gender 
identity (transgender) are often collectively 
referred to as members of the LGBT (lesbian/
gay/bisexual/transgender) community. A few key 
issues must be addressed when considering the 
“LGBT community”:
 1.  While sexual expression is a key difference 
between LGBT and non-LGBT persons, 
LGBT persons may differ from their hetero-
sexual peers in non-sexual ways (e.g. social 
support structures). Holistic assessment of the 
particular needs of an LGBT person includes 
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understanding of LGBT issues that may not 
specifi cally relate to sexual activity. 
 2.  Although many refer to the “LGBT commu-
nity”, it is important to recognize that there is no 
single unifi ed LGBT community; rather, there 
are diverse communities of lesbian, gay, bisex-
ual, and transgender persons who frequently 
have a common interest in advocacy and educa-
tion of the public at large about sexual and 
gender diversity. 
 3.  LGBT is the most familiar acronym to most 
individuals. The terms “queer” or “question-
ing” have been adopted by some individuals 
who do not identify as heterosexual nor as les-
bian, gay, bisexual, or transgender. The acro-
nym LGBT is sometimes extended to read 
LGBTQ; for the sake of convenience we will 
restrict use in this manuscript to LGBT while 
acknowledging that some gender/sexuality 
variant persons may not identify with the term 
“LGBT”. Medical concerns related to patients 
affected by differences of sex development 
are discussed in Chap.  22 . 
 Talking to LGBT Patients 
 Personal issues and potentially embarrassing 
issue regarding sexuality and urinary function) 
are routinely discussed during urologic consulta-
tion. During the urologic visit, it is critical for a 
patient to feel empowered to share important 
aspects of his/her history without fear of judg-
ment or alienation from the provider. The intrin-
sic sensitivity of urologic issues is compounded 
when they must be discussed in the context of a 
patient with a non-normative sexual or gender 
identity. It is thus imperative that the provider 
strive to create an open and judgment-free envi-
ronment so that key pieces of the patient’s history 
can be incorporated into the evaluation and plan 
of treatment. 
 Because patients who do not disclose their 
sexual orientation and/or gender identity are at 
risk of worse health outcomes, health care pro-
viders must elicit these issues with sensitivity to 
ensure optimal patient care [ 1 ]. The provider 
should facilitate an environment where the 
patient is able to share this information without 
fear of recrimination [ 2 ]. Openness between 
patient and provider is critical to building of rap-
port and trust, which is fundamental to the thera-
peutic relationship [ 3 ]. Information on sexuality 
and gender is of particular relevance to urology 
as this specialty is concerned with medical issues 
germane to the genitals and sexual activity. 
 In establishing rapport with patients it is criti-
cal to use inclusive language and to avoid 
assumptions in eliciting the medical and sexual 
history. Specifi c examples include avoidance of 
gender-specifi c pronouns when referring to a 
patient’s sexual partner(s) and not presuming that 
an individual is heterosexual. Conversely, a prac-
titioner should not presume that an individual’s 
professed identity is concordant with their behav-
ior. Up to 7 % of American women 18–59 years 
of age report a sexual history with another 
women; over half of these women identify as het-
erosexual [ 4 ]. Similarly, estimates indicate that 
over 70 % of self-identifi ed lesbians have a his-
tory of sexual relationships with men; as many as 
6 % of lesbians in one study reported sex with a 
male partner within the past year [ 5 ]. In a similar 
fashion, there exist a population of men who 
report heterosexual orientation but engage in sex-
ual activities with other men [ 6 ]. Because there is 
often discrepancy between professed orientation 
and behavior (historical or current), some 
researchers favor the descriptive terms “men who 
have sex with men” (MSM) and “women who 
have sex with women” (WSW) to terms such as 
gay or lesbian, respectively. 
 Urologic Issues 
 Urinary Function 
 Normal urine production, storage and transport 
depend on the functioning and coordination of the 
kidneys, ureters, bladder, and urethra (Fig.  16.1 ).
 The kidneys continuously fi lter the blood, 
producing urine as the excretory byproduct. 
Urine is transported by peristalsis of the ureters 
from the kidneys to the urinary bladder, where it is 
stored until it can be conveniently evacuated [ 7 ]. 
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The bladder is a compliant hollow organ lined 
with mucosa overlaid on a muscular layer (the 
detrusor). The healthy bladder is compliant, 
meaning it can fi ll at low pressures and accom-
modate a large volume of fl uid. The urethra is the 
tube which urine passes from the urinary bladder 
during micturition. In men, the urethra passes 
through the prostate, which is a gland responsible 
for the production of seminal fl uid [ 7 ]. 
 In both men and women urine is held in the 
bladder by action of the internal and external ure-
thral sphincters. The  internal sphincter is located 
in the vicinity of the bladder neck and consists of 
involuntary smooth muscle under the control of 
the autonomic nervous system. The external uri-
nary  sphincter is located in the proximal portion 
of the urethra; this sphincter is contracted to pre-
vent unwanted leakage. The external urethral 
sphincter is under voluntary control. Normal 
storage of urine depends on compliance of the 
bladder, relaxation of the detrusor muscle, and 
adequate capacity to coapt the urethra. Failure of 
any of these mechanisms leads to incontinence 
(involuntary loss of urine).  Incontinence is subdi-
vided into  urgency incontinence (loss of urine 
with sudden overpowering urge) and  stress 
incontinence (loss of urine with ValSalva or other 
increase in intraabdominal pressure) [ 7 ]. 
 During urination, the brain receives sensory 
input that the bladder is full, triggering the cas-
cade of events leading to micturition. The brain 
sends a signal to the urethral sphincters to relax 
followed by contraction of the detrusor muscle, 
which surrounds the bladder. Squeezing of the 
detrusor muscle forces urine out of the bladder 
and through the urethra. Normal voiding depends 
on detrusor contraction, simultaneous relaxation 
of both urinary sphincters, and a low resistance 
urethra allowing for unobstructed urine fl ow. 
Failure of any of these mechanisms may lead to a 
variety of lower urinary tract symptoms ( LUTS). 
LUTS are common in both men and women and 
can lead to signifi cant impairment in quality of 
life [ 8 ,  9 ]. LUTS are commonly divided into 
“obstructive” or “irritative” categories [ 2 ,  10 ].
 Obstructive 
 1.  Weak urinary stream. 
 2.  Need to strain (Valsalva maneuver) with 
urination. 
 3.  Incomplete emptying, or a sensation of urine 
remaining in the bladder at the completion of 
a void. 
 Irritative 
 1.  Urinary urgency or the strong and immediate 
need to urinate without delay or warning. 
 2.  Urinary frequency defi ned as the need to void 
multiple times in an excessive and bother-
some way without a normal time interval gen-
erally <1–2 h. 
 3.  Nocturia or voiding multiple times during the 
night. 
 4.  Post Void Dribbling 
 The most common cause of  obstructive symp-
toms is increased urinary outfl ow resistance 
along the urethra. For men, this often is the result 
of an enlarged prostate or a urethral stricture 
(i.e. a scar of the urethral lumen from past injury 
or infection). In women obstructive symptoms 
can be due to kinking of the urethra, which can 
result from prolapse of the bladder or other 
 Fig. 16.1  This coronal view of the urinary tract shows 
the kidneys, which fi lter blood to create urine. Urine 
drains out through the ureters to be stored in the bladder, 
prior to evacuation (Image Courtesy, J. Ehrenfeld) 
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organs through the vagina, displacing the path of 
the urethra and increasing outfl ow urinary resis-
tance. In severe cases obstructive LUTS can pro-
duce a form of incontinence called “ overfl ow 
incontinence ” in which the bladder does not 
completely empty and urine dribbles out from the 
urethra when intravesical pressure becomes high 
enough to exceed urethral closure pressure [ 11 ]. 
 Irritative symptoms often have a more compli-
cated pathophysiology but are generally due to an 
over-activity of the detrusor muscle; this stimu-
lates a spasm-like sensation that triggers a sensa-
tion of needing to void. Detrusor overactivity 
may be secondary to spinal injury, neurodegen-
erative conditions, bladder irritation from infl am-
mation or infection, or it may be idiopathic. 
 LUTS are a signifi cant impediment to overall 
quality of life and represent a substantial cost in 
terms of healthcare expenditures and loss of pro-
ductivity [ 12 ]. Loss of urinary  control may also 
contribute to social isolation and depression [ 13 ]. 
Aside from symptomatic bother, inability to ade-
quately void predisposes patients to urinary tract 
infection, urolithiasis, and in extreme cases renal 
failure due to back pressure on the kidneys. 
 LUTS in Men 
 The prostate is the organ most commonly associ-
ated with LUTS in men, primarily due to benign 
prostate  hypertrophy (BPH, also referred to as 
Benign Prostate Enlargement  BPE ). In  BPH 
there is enlargement of the prostate gland, lead-
ing to compression of the urethra and narrowing 
of urethral caliber (Fig.  16.2 ). This tends to 
restrict urine outfl ow. BPH is strongly associated 
with age although the degree of bother from BPH 
does not always correlate with the degree of glan-
dular enlargement. While enlargement of the 
prostate plays an important role, local and sys-
temic infl ammation may also contribute to symp-
 Fig. 16.2  Sagittal 
Section of the male 
pelvis. The prostate 
surrounds the urethra but 
does not protrude into 
the urethral lumen. In 
the setting of BPE or 
BPH (not shown) the 
urethra is compressed by 
the enlarged prostate and 
urine fl ow is restricted 
(Image Courtesy, 
J. Ehrenfeld) 
 Helpful Hint 
 It is important to recognize that there is 
often signifi cant overlap between obstruc-
tive and irritative symptoms; the  etiology 
of a patient’s LUTS may be multifactorial 
and may require urologic investigation to 
accurately diagnose [ 10 ]. 
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toms [ 14 ] and possibly even to hypertrophy by 
inducing cells to multiply and grow [ 15 ]. This 
 synergistic effect may accelerate prostate growth 
and progression of LUTS in men.
 The most common  infl ammatory triggers in 
the prostate include pathogens like viruses and 
bacteria. Men with a history of urinary tract infec-
tions and/or sexually transmitted infections (STI) 
are more likely to develop LUTS [ 16 ].  Progressive 
growth in the size of the prostate is also a contrib-
uting factor to LUTS in men.  Diabetes ,  obesity 
and the  metabolic syndrome have all been linked 
to an increase risk of LUTS [ 17 ]. 
 HIV infection is another important risk factor 
for LUTS. In a urodynamic study of HIV infected 
men with LUTS it was determined that the under-
lying cause of LUTS in 61 % of these men was 
neurological (e.g. cerebral toxoplasmosis and 
HIV encephalitis [ 18 ]. These data are from an era 
before the introduction of  Highly Active 
Retroviral Therapy (HART) and hence these neu-
rologic entities are much less common in con-
temporary HIV infected persons. In contemporary 
series HIV associated LUTS are thought to be 
related to pro-infl ammatory nature of the disease 
process, increased risk of UTI, and/or neuro-
pathic injury to the detrusor nerves [ 19 ,  20 ]. 
 Major  depression is common in men with 
LUTS.  Depression has been shown to increase 
infl ammatory markers in patients and it is thought 
that these effects contribute to the pathophysiol-
ogy of LUTS [ 21 ,  22 ]. A study by Johnson et al. 
in 2010 found that men suffering from depression 
had higher urinary symptom scores (worse void-
ing symptoms) as compared to healthy controls 
[ 23 ]. Breyer et al. also found a signifi cant asso-
ciation between depression and suicidal ideation 
and lower urinary tract symptoms [ 24 ]. In addi-
tion to the infl ammatory response induced by the 
depressive state, it is also hypothesized that the 
pathologic synthesis and regulation of serotonin 
observed in depressed individuals may place 
these same individuals at risk for developing 
 idiopathic detrusor overactivity [ 25 ]. Since the 
detrusor muscle contraction is responsible for 
normal voiding, instability of this muscle could 
lead to increased urinary symptoms. 
 Although the  physiology of LUTS is similar 
amongst all men regardless of sexual behavior, 
specifi c risks have been identifi ed in  MSM. MSM 
have a higher rate of STI compared to the general 
population [ 26 ,  27 ]. Breyer et al. reported that 
MSM with a history of gonorrhea, urinary tract 
infections, and prostatitis were more likely to 
report LUTS compared to their MSM peers [ 28 ]. 
In a related study Breyer et al. reported that men 
with AIDS were more likely to report moderate 
to severe lower urinary tract symptoms as 
 compared to non-HIV infected men as well as 
men with HIV but not AIDS (Fig.  16.3 ) [ 28 ].
 Similarly, depression is more prevalent in the 
LGBT community and has been identifi ed as a 
predictor of LUTS in MSM [ 28 ]. For these rea-
sons,  MSM should be screened for LUTS and 
counseled accordingly [ 29 ]. A common screen-
ing tool for urinary symptoms in men is the 
International Prostate Symptom Score ( IPSS ) 
(also known as the  American Urologic 
Association Symptom Score ) [ 30 ]. 
 LUTS  in Women 
 Symptoms and etiologies for LUTS and inconti-
nence in women differ markedly from what is 
observed in men, largely due to anatomic differ-
ences between genders. Obstructive LUTS are 
relatively infrequent in women but irritative 
symptoms occur at a high rate and women are at 
a much higher risk of incontinence than men due 
to markedly lower urethral resistance. Symptoms 
 Helpful Hint 
 While LUTS in men are commonly attrib-
uted to prostate pathology, bladder instabil-
ity may occur in men. Potential etiologies 
include neurologic lesions, chronic obstruc-
tion from BPH, urinary tract infections, and 
idiopathic causes. These possibilities should 
be considered when evaluating a male 
patient with LUTS. 
16 Urologic Issues in LGBT Health
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are often a result of changes in the pelvic fl oor 
musculature, which can occur after childbirth. 
These changes can cause kinking of the urethra 
resulting in obstructive symptoms, which can 
then evolve to include overactive symptoms from 
incomplete emptying of the bladder. 
 In addition, following menopause, changes in 
estrogen levels can result in the vaginal mucosa 
to become thinner and more friable. For, some 
women this can be manifested in irritation with 
voiding and result in increased urinary frequency 
and even recurrent urinary tract infections. 
 Lesbian and bisexual women have higher rates 
of obesity compared to heterosexual women [ 31 ], 
a condition that has been associated with greater 
risk of LUTS [ 32 ]. At the same time, lesbian 
women are less likely to have a history of preg-
nancy, which is a risk factor for incontinence. 
Whether WSW have a signifi cantly different 
prevalence for LUTS/incontinence compared to 
their heterosexual peers is unclear; unpublished 
data from our group indicate that the prevalence 
of LUTS and incontinence in WSW is generally 
similar to what is observed in non-WSW females 
(Shindel, unpublished data). However, the high 
prevalence of LUTS/incontinence in women in 
general dictates that WSW be screened and 
appropriately treated for LUTS/incontinence. 
 Treatment of LUTS 
 Treatment options for lower urinary tract symp-
toms range from behavioral modifi cation to med-
ications to surgical interventions. Picking the 
appropriate therapy depends on the individual 
needs of the patient and should be based on the 
patient’s reported symptoms. Treatment should 
be initiated if symptoms are bothersome or if 
symptoms are presenting a risk to a patient’s 
health (e.g. worsening renal function, recurrent 
urinary tract infections, urolithiasis). 
 Behavioral interventions are often the fi rst line 
of therapy for LUTS. Men or women with bother-
some LUTS can try to void regularly (i.e. every 3 
h) or perform double voiding which means void-
ing to presumed completed, waiting, and then 
attempt to void again immediately to excrete any 
0% 10% 20% 30% 40% 50% 60% 70% 80%
HIV(-)/AIDS(-)
HIV(+)/AIDS(-)
HIV(+)/AIDS(+)
Percent Prevalence of LUTS in MSM by HIV/AIDS
Status, (p<0.01)
Severe LUTS (IPSS 20-35) Moderate LUTS (IPSS 8-19) Mild LUTS (IPSS 0-7)
 Fig. 16.3  Prevalence of LUTS in MSM by HIV/AIDS Status 
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remaining urine from the bladder. Such behaviors 
can improve bladder emptying and decrease 
LUTS. Other interventions include decreasing 
oral fl uid intake in the evening and at night to 
decrease the severity of nocturia. Changing the 
dosing of diuretics to earlier in the day can also 
improve nighttime urinary symptoms. Finally, 
avoiding bladder irritants like caffeine, citrus, 
alcohol, carbonated beverages, and spicy foods 
can help to decrease bladder over activity. 
 For LUTS refractory to behavioral modifi cation, 
three classes of medications are frequently 
prescribed.  The fi rst three categories are spe-
cifi cally indicated for natal men and are not 
FDA approved for use in natal women. 
 Alpha-blockers (e.g. terazosin, doxazosin, tam-
sulosin, sildosin, alfuzosin, etc.) block adren-
ergic nerve endings which are responsible for 
contraction of smooth muscle in the vicinity 
of the internal urethral sphincter and prostate; 
this has the effect of increasing the luminal 
diameter of the prostatic urethra during void-
ing and improving urinary fl ow. Symptoms 
can improve immediately but generally take 
2–3 weeks for noticeable relief. Side effects 
including weakness, orthostatic hypotension 
and anejaculation. The rates of orthostatsis/
weakness are markedly lower in modern 
selective alpha blockers. However, alpha 
blockers may have a synergistic hypotensive 
effect when taking with inhibitors of  phospho-
diesterase type 5 (PDE5I ) that are used to pro-
mote penile erection (e.g. sildenafi l, vardenafi l, 
tadalafi l, avanafi l); patients should be cau-
tioned about this potential drug interaction 
and advised to take these classes of medica-
tions at least 4 h apart in time. Although ortho-
static symptoms are markedly less with 
modern alpha blockers anejaculation is more 
common (~14–35 %) [ 33 ,  34 ]. Ejaculatory 
disturbance may be of great signifi cant to 
MSM as ejaculation has been shown to be an 
important sign of sexual gratifi cation in this 
population [ 35 ]. 
 5-alpha reductase inhibitors ( 5ARI , e.g. fi nas-
teride, dutasteride) inhibit the enzyme 5-alpha 
reductase which converts testosterone to dihy-
drotestosterone, the primary active androgen 
in the prostate. This results in decreased 
growth of the prostate and can even cause the 
prostate to shrink in size up to about 20 %. 
 5ARI are most effective in men with very 
large prostates. 5ARI have also been shown in 
a randomized controlled trial to signifi cantly 
reduce the risk of BPH progression (e.g. uri-
nary retention, requirement for surgery, UTI, 
renal failure) when used as monotherapy or in 
combination with an alpha blocker. Men on 
this medication generally will have a halving 
of serum PSA (prostate specifi c antigen) so 
this must be taken into consideration when 
interpreting the screening test for prostate 
cancer. This medication does not work imme-
diately and may need to be taken regularly for 
6 months before noticeable improvements are 
seen. Reported side effects include decreased 
sex drive, smaller amount of ejaculate, erectile 
dysfunction, and gynecomastia [ 36 ]. 
 Tadalafi l is a selective inhibitor of the enzyme 
phosphodiesterase type 5. This drug was ini-
tially approved for management of erectile 
dysfunction (ED) in men but has also estab-
lished effi cacy in the management of LUTS in 
men with BPH when taken as a daily dose. 
While the subjective benefi t of tadalafi l for 
LUTS is established, treatment with this drug 
has not been shown to improve objective mea-
sures such as urine fl ow rate and post void 
residual urine. Side effects of tadalafi l include 
congestion, stuffy nose, headache, and myal-
gias [ 37 ]. 
 Anticholinergics (e.g. oxybutynin, tolterodine, 
solfenacin, darifenacin, trospium) block cho-
linergic nerve endings which are responsible 
for initiation of bladder contraction and can be 
helpful for patients with overactive bladder 
 Helpful Hint 
 Behavioral interventions can often improve 
urinary symptoms without the potential 
risks of medication or surgery. 
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symptoms. By decreasing the intensity of blad-
der contractions, patients with irritative LUTS 
may be able to postpone voiding and decrease 
urinary frequency. The medication works 
quickly and its effects are generally noticed in 
the fi rst days to weeks of stable dosage. Side 
effects include dry mouth, dizziness, constipa-
tion and drowsiness. There is some concern 
that these drugs may precipitate urinary reten-
tion in patients with pronounced urethral 
obstruction. Anti-cholinergics should not be 
used in persons with narrow angle glaucoma 
and should be used with caution in elderly per-
sons using other anti-cholinergic or nervous 
system active drugs due to increased risk of 
mental status change [ 38 ]. 
 For some patients, medications and behavioral 
changes are not suffi cient to treat LUTS. These 
patients should be referred to a urologist for 
counseling and discussion of surgical treatment 
options. Examples of surgical treatments include 
Transurethral Resection of the Prostate ( TURP ) 
in men with BPH,  urethral sling surgery for 
incontinence (primarily in women but useful in 
some cases for men), and  intravesical injection of 
botulinum toxin in patients of any gender who 
have refractory bladder overactivity [ 39 ]. 
 Sexual Behavior and Health 
 Clear and important differences exist regarding 
sexual behavior between heterosexual and LGBT 
patients. Perhaps most important for clinicians is 
understanding the important and unique differ-
ences in sexual dysfunction among these popula-
tions in order to properly screen and treat LGBT 
persons. Data regarding same-sex sexual behavior 
has been dominated by the role sexual behavior 
and dysfunction on the impact of HIV transmis-
sion in MSM [ 40 ,  41 ]. Existing studies on sexual 
function/satisfaction are often qualitative in nature, 
include small populations, and utilize non-vali-
dated metrics or single item questions to elucidate 
information. This last limitation stems from the 
fact that the majority of validated instruments for 
assessment of sexual function use language geared 
towards heterosexuals and have not been validated 
in the LGBT population [ 42 ,  43 ]. 
 Taking an appropriate sexual history is funda-
mental to promoting sexual wellness and the fun-
damental skills relevant to taking a sexual health 
history in cis-gendered heterosexual persons 
apply to sexual health history in LGBT persons. 
However,  normalizing statements (e.g. “Many of 
my patients…”, “Some people have sex with 
women, some with men, some with both, and 
others with neither.”) and open ended questions 
(e.g. “What questions do you have about your 
sexual health?”) are of particular importance in 
comfortable sexual health inquiry for LGBT per-
sons. “Yes/no” questions can still be useful in 
initiating the conversation (e.g. “Do you have any 
concerns or questions about sexuality that you 
would like to address during this visit?”) Further 
questioning as to the type of sexual activity the 
patient engages can be important for many 
aspects of the urologic assessment ranging from 
risks for sexually transmitted infections to coun-
seling for treatment of prostate cancer. Asking 
the patient if they engage in oral, anal, or vaginal 
sex and clarifying if the behavior is receptive or 
insertive can accurately characterize the patient’s 
sexual activity. 
 The  Sexual Response Cycle 
 Williams Masters and Virginia Johnson are cred-
ited with the fi rst large scale systematic investiga-
tion of sexual response in men and women. From 
their observations Masters and Johnson devel-
oped a four phase sexual response cycle consist-
ing of Arousal, Plateau, Orgasm, and Resolution 
[ 44 ]. The sex therapist Helen Singer Kaplan 
modifi ed this linear response cycle to incorporate 
a desire phase which precedes arousal [ 45 ]. 
 Helpful Hint 
 There is great variability in sexual expres-
sion amongst LGBT persons; it if helpful to 
understand the exact sort of sexual activity 
the patient engages in. 
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Alternative models for sexual response in women 
that are more circular in nature have been pro-
posed by several experts [ 46 ]. While these newer 
models have some merit the linear response mod-
els remain very useful for classifi cation of sexual 
disruptions. An outline of the physiological 
events associated with difference phases of the 
sexual response cycle (omitting plateau) and 
classifi cation of specifi c disruptions of these 
phases is presented in Table  16.1 . 
 Sexual Function in  Natal Men 
 Much has been uncovered in recent years regard-
ing the complexities involved in male sexual 
behavior. From arousal to erection to ejaculation, 
sexual function requires a complex coordination 
of incoming and outgoing stimuli all presided 
over by the brain. Brain imaging studies of men 
during sexual activity have identifi ed the mesodi-
encephalic transition zone (an area in the center 
of the brain) as the area which receives sensory 
information from the genitals, anus, rectum and 
prostate during sexual activity that is carried to 
the brain by the spinal cord during ejaculation 
[ 47 ]. This area contains dopaminergic nerve cells 
controlled by dopamine—a neurotransmitter 
linked with rewarding behaviors—and may 
explain why genital and anal stimulation is so 
strongly pleasurable and rewarding [ 48 ]. 
 Penile erection is the best understood aspect of 
male sexuality and the issue most amenable to 
treatment. Erection of the penis occurs via dilation 
of the cavernous arteries, which supply blood to 
the corpora cavernosa of the penis. The vascular 
events that drive penile erection are mediated by a 
complex interplay of the cavernous nerves which 
innervate the cavernous arteries. Release of nitric 
oxide from these nerves activates vascular guanyl-
ate cyclase, which in turns produces downstream 
molecular events that trigger muscular smooth 
relaxation in the arteries supplying the penis. With 
vasodilation, penile blood fl ow increases and the 
erectile tissue of the penis becomes engorged. 
As this tissue expands and becomes tumescent the 
emissary veins which drain the corpora cavernosa 
are compressed against the tunica albuginea of the 
corpora cavernosa; this has the effect of restricting 
blood fl ow out of the penis and leads to rigid penile 
erection [ 49 ]. 
 Due to variation in sexual practice patterns the 
anus, prostate, and rectum are relevant to MSM 
as many (but not all) MSM engage in anal sex. 
The prostate is clearly a “sexual” erogenous zone 
and one that can provide sexual pleasure follow-
ing digital stimulation or through anal receptive 
 Table 16.1  The sexual response cycle in biologically female and male persons and common nomenclature for sexual 
issues of each phase 
 Biologically male  Biologically female 
 Physiological signs  Disruption classifi ed 
as: 
 Physiological signs  Disruption 
classifi ed as: 
 Desire  Pupillary dilation, 
tachycardia, tachypnea 
 Hypoactive sexual 
desire disorder 
 Pupillary dilation, 
tachycardia, tachypnea 
 Hypoactive sexual 
desire disorder 
 Arousal  Penile erection, scrotal 
contraction, nipple 
erection 
 Erectile dysfunction  Vulvar and clitoral swelling, 
vaginal lubrication and 
lengthening, nipple erection 
 Sexual arousal 
disorder (genital or 
subjective) 
 Orgasm  Ejaculation, muscular 
contractions, 
satisfaction, pleasure 
 Premature ejaculation, 
delayed ejaculation, 
anorgasmia 
 Muscular contractions in 
vagina, uterus, anus, 
satisfaction/pleasure 
 Female orgasmic 
disorder 
 Resolution  Detumescence of the 
penis, return to resting 
state 
 Priapism  Cessation of vaginal 
lubrication and lengthening, 
return to resting state 
 Persistent genital 
arousal disorder 
 Helpful Hint 
 In virtually all cases of sexual problem/
dysfunction there are both biological and 
psychological factors at play. 
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intercourse though researchers know little on the 
innervation pathways involved. It is important 
that patients be educated about the critical role 
that the prostate plays in sexual activity espe-
cially if the patient engages in anal receptive 
intercourse. 
 The neurologic and vascular systems are 
essential components of erectile response; hence, 
vascular diseases (e.g. diabetes, hypertension, 
hypercholesterolemia, tobacco use, obesity, lack 
of exercise) and nervous system lesions (e.g. 
spinal cord transaction, cavernous nerve injury 
during pelvic surgery) are major risk factors for 
ED. Other common causes of trouble with erec-
tions include medication side effects (particularly 
beta blockers, thiazide diuretics, and anti- 
depressants), testosterone defi ciency, and psy-
chosocial issues within the patient or between 
patient and partner (s) [ 49 ]. 
 Sexual Dysfunction  in MSM 
 Erectile  Dysfunction 
 Existing data suggest that rates of erectile dys-
function ( ED ) are higher in gay/bisexual men 
compared to their heterosexual peers. Bancroft 
et al. reported on a sample of 2937 men and 
found that only 42 % of gay identifi ed men 
“never” experienced ED as compared to 54 % of 
heterosexual men [ 50 ]. An internet study investi-
gated sexual wellness in osteopathic and allo-
pathic medical schools in North America and 
compared rates of self reported sexual dysfunc-
tion. It was determined that ED was more preva-
lent amongst gay or bisexual identifi ed men as 
compared to heterosexual men [ 51 ]. This fi nding 
of increased ED among MSM was also echoed in 
a study by Vansintejan et al. out of Belgian. The 
authors found that almost half of MSM sampled 
reported some diffi culty with getting an erection. 
Factors associated with ED included increased 
age, single relationship status, versatile or pas-
sive sex role, and decreased libido [ 52 ]. Because 
gay men have a higher prevalence for tobacco 
and drug use compared to heterosexual men, 
their risk of ED is likely to be greater [ 53 ]. 
 One major diffi culty in studying erectile dys-
function in MSM is the fact that the standardized 
questionnaires commonly used in contemporary 
ED research are validated for use in heterosexual 
encounters only. Coyne et al. did validate a ver-
sion of the International Index of Erectile Function 
(IIEF) in a population of HIV infected men who 
have sex with men. This instrument was used by 
Shindel et al. in an internet survey of sexual func-
tion in MSM. It was determined that ED was 
associated with increasing age (Fig.  16.4 ), AIDS, 
and LUTS [ 54 ]. LUTS and younger age were 
associated with greater risk of PE [ 54 ]. 
 Premature  Ejaculation and Other 
Sexual Concerns 
 A number of other sexual problems may occur in 
men, including premature  ejaculation (PE, 
defi ned most recently by the International Society 
for Sexual Medicine as ejaculation occurring in 
1 min or less of penetration and associated with 
loss of sense of control and distress) [ 55 ]. It is 
noted that the defi nition applicable only to coital 
intercourse. The intent of these authors was not 
be to exclusionary; however, it was concluded 
that there was currently insuffi cient objective evi-
dence to incorporate non-coital intercourse into 
the defi nition of PE. Until data on clinically rele-
vant PE in MSM is available it is advised that 
clinicians and researchers use the same ISSM cri-
teria for the diagnosis of PE in MSM [ 55 ]. 
 Most contemporary reports suggest that the 
prevalence of early ejaculation is similar to 
slightly less in MSM compared to their hetero-
sexual peers [ 50 ,  51 ,  56 ,  57 ]. Early ejaculation 
associated with bother is reported by between 15 
and 34 % of MSM [ 54 ,  58 ,  59 ]. Controversy per-
sists on the true burden of clinically relevant 
early ejaculation in general, let along in 
MSM. Most studies suggesting a ~30 % preva-
lence are based on single item reporting of sub-
jective experiences rather than the most stringent 
criteria and hence it is likely that the true preva-
lence of clinical PE is less than 5 % [ 55 ,  60 ]. 
 MSM with severe voiding symptoms, HIV 
infection, and who experience social recrimination 
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appear to have lower risk of early ejaculation 
compared to their MSM peers [ 59 ,  61 ,  62 ]. 
 Aside from ED and PE, men may experience 
bothersome declines in sexual desire (aka hypo-
active sexual desires disorder or low libido), 
diffi culty attaining orgasm (anorgasmia), disrup-
tion of ejaculation (retrograde ejaculation or ane-
jaculation), and Peyronie’s Disease (an acquire 
 deformity of the penis). These issues are less well 
understood but can pose a signifi cant impediment 
to sexual satisfaction. A careful history can help 
elucidate the exact nature of sexual complaints in 
men; it should be borne in mind that many sexual 
concerns may be comorbid. 
 Sexual Dysfunction, HIV, and AIDS 
 AIDS has been identifi ed as signifi cant risk factor 
for developing ED and/or premature ejaculation 
amongst MSM. Hypotheses for the etiology of this 
connection range from prolonged use of HART, 
exposure to opportunistic infections and, low CD4 
counts although these associations have been 
inconsistently demonstrated to increase the preva-
lence of HIV [ 63 – 65 ]. Research by Hart attempted 
to identify differential risk factors for ED compar-
ing  HIV negative and positive MSM. The authors 
found an increased risk of ED among HIV(+) men 
(21 %) as compared to HIV (−) (16 %) despite the 
HIV (+) cohort having a younger median age. Risk 
factors for ED in HIV (−) men were older age (age 
55+ versus age ≤40; 112 % increase), Black race 
(88 % increase), and cumulative years of cigarette 
smoking in pack-years (9 % increase). In HIV (+) 
men, risk factors were years of antihypertensive 
use and cumulative years of antidepressant use. 
Interestingly, HAART adherence years and CD4+ 
cell count were not found to signifi cantly predict 
likelihood of ED [ 53 ]. The authors suggested that it 
the HIV—related medical comorbidities which 
may explain the increased prevalence of ED as 
opposed to a direct effect of the virus. Additional 
potential factors Testosterone defi ciency is com-
mon in HIV positive persons and this may predis-
pose to declines in libido and erectile capacity 
[ 66 ,  67 ]. Finally, the substantial psychosocial 
stressors of HIV infection (stigma, concern about 
infecting others, etc) may contribute to sexual 
issues in HIV positive persons [ 68 ]. 
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 Fig. 16.4  Prevalence of ED in MSM by decade of life 
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 In a study by Shindel, greater prevalence of 
erectile dysfunction was identifi ed in men with 
progressive  HIV infection 40–59 years of age as 
compared to HIV-negative men of similar age. 
When the authors controlled for other variables 
including age, number of sexual partners, and 
condom use they found that HIV alone was not a 
risk for ED but HIV with AIDS was associated 
with greater odds of ED [ 69 ]. 
 Neither HIV nor AIDS was associated with an 
increased prevalence of early ejaculation in this 
study. Interestingly, use of  phosphodiesterase 5 
(PDE5) inhibitor drugs was found to be more 
common among HIV-infected men. In addition, 
HIV (+) men were more likely to have sought 
medical attention for sexual dysfunction as com-
pared to HIV (−) MSM [ 69 ]. 
 Management of Sexual Concerns 
in Gay Men 
 Medical therapies for ED include oral phospho-
diereterase type 5 inhibitors (PDE5I), vacuum 
erection devices (VED), intracavernosal injection 
therapy (ICI), intraurethral prostaglandin sup-
positories, and surgical implantation of infl atable 
or malleable penile prostheses [ 69 ]. 
 PDE5I drugs are the fi rst line agents of choice 
 in  medical management of ED. In the United 
States four PDE5I are currently available; silde-
nafi l (Viagra ® ), vardenafi l (Levitra ® or Staxyn ® ), 
tadalafi l (Cialis ® ), and avanafi l (Stendra ® ). Other 
PDE5I are approved for use in other regions of 
the world. These drugs are highly effective but 
must be taken at least 1–2 h before planned inter-
course. Potential side effects include congestion, 
headache, fl ushing, visual disturbance, and 
myalgia. Side effects are typically mild and self- 
limited. PDE5I should not be used in patients 
taking nitrate based therapy for angina and 
should not be taken within 4 h of alpha blocker 
medications [ 70 ]. 
 Second and third line therapies for ED are 
often effective in cases where oral pharmacother-
apy fails [ 70 ]. A complete discussion of these 
modalities is beyond the scope of this chapter but 
interested readers are referred to recent publications 
on management of ED in men [ 70 ] and to national 
and international organizations dedicated to sex-
ual wellness in men such as the Sexual Medicine 
Society of North America ( www.smsna.org ) and 
the International Society for Sexual Medicine 
( www.ISSM.info ) 
 ED  in HIV Positive Men 
 The issue of ED in HIV positive men is one of 
marked public health consequence as ED has 
been associated with failure to utilize safer sex 
practices (i.e. condoms) [ 68 ]. The treatment of 
ED in HIV positive persons has been controver-
sial in the past due to concerns that this might 
promote sexual transmission of the virus [ 71 ]. 
A pilot study by Goltz attempted to identify any 
possible increased risk for contracting STIs 
amongst MSM receiving therapy for erectile dys-
function. The authors found that 1/3 of the sam-
ple had engaged in unprotected anal sex at the 
last erectile dysfunction medication use. Risks 
for engaging in unprotected sex were younger 
age and receiving the medication from the sexual 
partner [ 72 ]. 
 While counseling on safer sex practices should 
accompany provision of erectogenic therapy in 
all contexts, there are no data suggesting that 
treatment of ED in and of itself increases risk of 
HIV infection. Treatment of ED may help some 
men with marginal erectile capacity retain erec-
tions despite condom use, thus facilitating safer 
sex [ 73 ]. Respect for persons and social justice 
are fundamental tenets of medical practice and 
indicate that HIV positive men with ED receive 
appropriate counseling and treatment for sexual 
issues, including ED [ 74 ]. 
 Management of  Other Sexual 
Problems in Men 
 Hypoactive sexual desire disorder, orgasmic dys-
function, and Peyronie’s Disease (a condition of 
acquired deformity of the penis) are present in 
gay men but are poorly characterized. Management 
of these concerns in gay men should follow 
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established treatment protocols, including attention 
to general health, relationship status, and medica-
tions that may contribute to sexual issues (e.g. 
beta blockers, thiazide diuretics, antidepressants, 
anti-androgens, etc). It should be borne in mind 
that there is only one FDA approved medical ther-
apy for Peyronie’s Disease (injectable collage-
nase) and no approved pharmacotherapy for any 
other sexual concern in men. 
 Sexual Function in  Natal Women 
 Scientifi c understanding of female sexual 
response lags far behind where we stand with 
respect to understanding of male sexual response. 
In general the same molecular and vascular events 
occur during female sexual arousal although the 
end result is markedly different from what is 
observed in men [ 75 ]. The clitoris becomes erect 
in a fashion similar to the penis but does not 
become as rigid due to size and the relative thin-
ness of the clitoral tunica. Vasodilation also plays 
an important role in promoting vaginal engorge-
ment, lengthening, and lubrication [ 75 ]. There are 
no glandular elements within the vagina that pro-
duce lubrication. However, with increased vascu-
lar engorgement of the vaginal submucosa oncotic 
pressure leads to production of a transudative 
fl uid that is passed through aquaporins on the 
vaginal mucosa into the vaginal lumen [ 76 ,  77 ]. 
 Vascular and neurologic health factors in 
women have not been clearly and universally 
linked to sexual distress/dissatisfaction as they 
have been in men although women with severe 
injuries (e.g. spinal cord injury) do have marked 
impairments of sexual function [ 78 ]. 
 Sexual Dysfunction  in WSW 
 Public health concerns about HIV spawned inter-
est from the research community on sexual well-
ness in gay men; sexual wellness in lesbian and 
bisexual WSW remains very poorly studied in 
the mainstream biomedical literature. There is a 
dearth of validated tools for the quantitative 
assessment of sexual function in lesbian women. 
Tracy and Junginger developed a version of the 
Female Sexual Function Index (FSFI) for use in 
lesbian women. The FSFI explores six domains 
relevant to female sexuality; Desire, Arousal, 
Lubrication, Orgasm, Satisfaction, and Pain. 
Women with lower scores on this index were 
identifi ed to have “higher risk for sexual dysfunc-
tion.” In the initial validation study, older age was 
associated with decreased sexual desire and over-
all sexual function. Stress was associated with 
worse sexual function whereas satisfying rela-
tionship with a partner were associated with bet-
ter sexual function [ 79 ]. 
 Shindel et al. utilized a version of this FSFI in 
an internet study of sexual function in 1566 
WSW. Risk of distress sexual problems was cal-
culated using previously established cut-off scores 
for the FSFI which were shown to approximate 
endorsement of sexual dissatisfaction in this 
cohort. After multivariable adjustment nulligravid 
women, women with OAB, and women with no 
partners or non-female partners were found to be 
at greatest risk of distress sexual issues [ 61 ]. 
 There is a common perception among both pro-
viders and patients that STI risk is low in same-sex 
encounters between women. This may predispose 
WSW to entirely preventable STI. A study on bar-
rier use in WSW was derived from this same data 
set and indicated that many WSW do not use bar-
riers during sexual encounters, even outside the 
context of a monogamous relationship [ 80 ]. These 
data speak to the need for education on safer sex 
practices for WSW [ 5 ,  81 ,  82 ]. 
 Shindel et al. found that while almost a quarter 
of the WSW sample reported symptoms of sexual 
dysfunction, only 11 % had actually sought help 
from a physician for these problems [ 61 ]. This 
highlights the importance of sexual health screen-
ing by physicians to help identify at risk patients 
and provide intervention to help improve sexual 
health in general but particularly in WSW. 
 Biomedical treatment options for sexual dys-
function in women in general are very limited; a 
selective estrogen receptor modulator has been 
approved for management of dyspareunia from 
vaginal penetration [ 83 ]. Other pharmaceuticals 
are used off label by some experts. A discussion 
of these medical treatment modalities is beyond 
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the scope of this chapter but interested readers are 
referred to recent publication on this topic and 
the International Society for the Study of 
Women’s Sexual Health (www.ISSWSH.org) for 
more information. Attention to psychosocial fac-
tors and relationship context remains an important 
consideration for sexual concerns in women. 
 Genitourinary Malignancy 
 Prostate Cancer in  MSM 
 Prostate cancer is the number one noncutaneous 
cancer in men with a lifetime risk of the malig-
nancy of almost 17 % [ 84 ]. No study has ever 
demonstrated an increased risk or incidence of 
prostate cancer in MSM. However, MSM are 
known to be less aware of the pathophysiology of 
prostate cancer and the impacts of its treatment as 
compared to their heterosexual counterparts [ 85 ]. 
Many factors contribute to this knowledge gap 
between MSM and heterosexual patients regard-
ing prostate cancer and the effects of its treatment. 
The aforementioned concerns about disclosure of 
gay identity to a provider may dissuade some 
MSM from mentioning their particular concerns 
about sexual function to their provider [ 86 ]. 
Furthermore, the vast majority of survey tools for 
assessment of treatment response after prostate 
cancer have a heterosexist focus (e.g. question-
naires that ask if erection is suffi cient for vaginal 
penetration) [ 87 ]. 
 Given recent trends towards early treatment of 
prostate cancer the majority of the negative 
effects of the disease arise from treatment and not 
the malignancy itself. Treatments for prostate 
cancer include prostatectomy, external beam 
radiation therapy, brachytherapy and hormone 
deprivation therapy. Although these interventions 
can result in excellent disease free survival ben-
efi t, they also can result in signifi cant comorbidi-
ties. The most common side effects resulting 
from prostate cancer treatment include ED, loss 
of ejaculation, painful anal receptive intercourse, 
urinary incontinence, and penile shortening. 
These side effects can have important conse-
quences on quality of life for all men. 
 Although MSM and heterosexual men have 
similar concerns regarding prostate cancer and 
desire for cure, there are several unique differences 
regarding sexual behavior, which can impact the 
experience of the potential side effects. Although 
anal intercourse is not an exclusively gay male 
practice nor is it practiced by all MSM, it is more 
frequent in MSM. Anal penetration requires a more 
rigid erection than vaginal penetration due to anal 
muscle tone. Hence, even a small decrease in the 
fi rmness of the erection may have a greater impact 
on sexual performance for MSM who penetrate 
their partner anally (tops) as compared to hetero-
sexual men engaging in vaginal intercourse. Anal 
receptive partners (bottoms) may experience plea-
sure from stimulation of the prostate gland. Loss of 
the prostate to surgery, rectal wall fi brosis from 
radiation, or anatomical changes in the pelvis 
which predispose men to anodyspareunia may 
exert a disproportionate infl uence on sexual enjoy-
ment for MSM who bottom. 
 Despite an obvious impact of prostate cancer 
treatment on anal intercourse the paucity of 
research on this behavior makes counseling 
extremely diffi cult. Clinicians should ask patients 
(particularly MSM) preoperatively about the 
importance of insertive and receptive anal inter-
course to their sexual expression. Pending the 
results of this revelation, clinicians can at least 
introduce the possibility of side effects following 
treatment and may even use this clinically rele-
vant data to inform the type of intervention 
recommended. 
 The importance of ejaculation has also been 
demonstrated to be higher amongst MSM as 
compared to heterosexual men. It has been 
hypothesized that ejaculation is an important sign 
 Helpful Hint 
 All men (including gay and bisexual men) 
are at risk for prostate cancer. Screening for 
prostate cancer is controversial but should 
be discussed with all men regardless of 
sexual orientation. 
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of sexual gratifi cation among MSM. Furthermore, 
Wassersug hypothesized that the impact of the 
HIV epidemic changed the act of ejaculation 
making a visible ejaculation important from a 
disease transmission standpoint [ 35 ]. Given that 
ejaculation is dependent on an intact prostate, it 
is very important to counsel patients on the likeli-
hood of ejaculation loss after surgery or radiation 
for prostate cancer. 
 Research also suggests that penis size plays a 
more important role in the psychosexual health of 
MSM, in that men with larger penises report 
improved health. A study by Grov et al. found 
that men with “below average” penis size fared 
signifi cantly worse on a multifaceted score of 
psychosocial adjustment [ 88 ]. Given the inci-
dence of penile shortening has been shown to be 
as high as 68–71 % of men following radical 
prostatectomy with a mean decrease of 1.1–
4.0 cm [ 89 ,  90 ], it is important that MSM be 
informed of this potential side effect. 
 Qualitative research performed by Hartman 
et al. of same sex couples impacted by sexual 
dysfunction following radical prostatectomy 
highlight important differences between hetero-
sexual and same sex relationships [ 91 ]. For 
example, navigating changing sexual roles fol-
lowing surgery is a unique challenge faced by 
same sex couples. For some couples, sexual roles 
may include one partner preferring anal receptive 
intercourse and the other anal insertive. Following 
surgery, these roles can evolve and impact the 
pre-surgical dynamic. Furthermore, the study 
identifi ed the use of open relationship as a coping 
strategy for maintaining sexual satisfaction that 
has not been identifi ed previously among hetero-
sexual couples [ 91 ]. Such studies, illustrate the 
importance of tailored pre and postoperative 
counseling for same sex couples focusing on 
their unique dynamics and needs. 
 Transgender Patients and Prostate 
Cancer 
 In male to female gender affi rming surgery (GAS), 
the prostate is normally left in place given its inti-
mate relationship with the urethra and the neuro-
vascular bundles involved in sexual arousal and 
orgasm. Prostatectomy also carries substantial 
potential for urinary and sexual morbidity so there 
is little motivation to remove it in GAS. Despite 
this fact, the rates of prostate cancer in male to 
female transgender patients are extremely low. The 
exact numbers are unknown but there have been a 
few case reports of transgender patients on hor-
mone therapy presenting with prostate cancer [ 92 , 
 93 ]. By defi nition, these patients have castrate 
resistant prostate cancer and are treated as such. It 
is thought that the lower rate of prostate cancer 
among transgender patients is the deprivation of 
testosterone. For this reason, transgender patients 
who are not on hormonal supplementation or on 
incomplete blockade carry a risk of developing 
prostate cancer and should be screened similarly to 
men. Although controversial, this screening should 
include shared decision making with a discussion 
of risks of screening based on family history. 
Following this conversation, prostate cancer 
screening can include a PSA serum level and digi-
tal rectal exam. The most important concept is that 
transgender patients still have a prostate and there-
fore carry a risk for prostate cancer which varies 
based on the duration of hormone therapy. 
 Bladder Cancer in LGBT Patients 
 The number one risk factor for developing uro-
thelial cell carcinoma of the bladder is cigarette 
smoking [ 94 – 97 ]. Given the increased incidence 
of smoking among LGBT persons as compared 
to heterosexuals [ 98 ], there is a resultant increase 
in risk for developing bladder cancer. For this 
reason, screening LGBT patients for smoking is 
critical, so smoking cessation counseling can be 
appropriately initiated. 
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